## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.7% below STRENGTH zone (3.0-6.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($339.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. State Street Corp Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251209T134902 | Somewhat-Bullish | Relevance: 99%
-  State Street Corp increased its stake in Stryker Corporation (NYSE:SYK) by 1.0% during the second quarter, now owning 3.91% of the company's stock valued at over $5.9 billion. Other institutional investors have also adjusted their positions, and analysts generally rate Stryker as a "Moderate Buy" with an average target price of $433.78. Recent insider transactions show executives selling shares.

**2. Seaview Investment Managers LLC Reduces Holdings in Stryker Corporation $SYK**
- Source: MarketBeat | 20251206T120024 | Neutral | Relevance: 99%
-  Seaview Investment Managers LLC significantly cut its stake in Stryker Corporation (NYSE:SYK) by 98.0% in Q2, selling 27,018 shares and retaining only 557 shares valued at $220,000. Despite this, Stryker reported strong Q3 earnings, beating estimates with $3.19 EPS and $6.06 billion in revenue, and analysts maintain a "Moderate Buy" consensus with an average price target of $433.78. Although institutional ownership stands at approximately 77%, company insiders have sold a substantial 522,118 shares worth roughly $185.4 million over the past three months.

**3. Cerity Partners LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251207T093034 | Neutral | Relevance: 99%
-  Cerity Partners LLC has increased its stake in Stryker Corporation (NYSE:SYK) by 16.1% during the second quarter, now owning 314,580 shares valued at $124.47 million. This move is part of broader institutional investor activity, although some insiders have recently sold shares. Analyst ratings for Stryker are generally positive, with a "Moderate Buy" consensus.

**4. Stryker (SYK) Shows 'Muscle' at Investor Day, but Truist Stays Neutral**
- Source: Finviz | 20251206T142900 | Somewhat-Bullish | Relevance: 99%
-  Truist analyst Richard Newitter maintained a Hold rating on Stryker Corporation (NYSE:SYK) and boosted its price target to $400, citing the company's strong position in the MedTech sector and ability to deliver operating leverage. Despite positive indicators like significant revenue growth and a 32-year dividend growth streak, Truist maintains a neutral stance, preferring companies with steady revenue growth and faster earnings. Stryker reported strong Q3 2025 results with $6.1 billion in revenue, growing over 10% year-over-year, and expects organic net sales growth of 9.8% to 10.2%.

**5. Stryker (SYK) Shows ‘Muscle’ at Investor Day, but Truist Stays Neutral**
- Source: Insider Monkey | 20251206T142900 | Somewhat-Bullish | Relevance: 98%
-  Stryker Corporation (NYSE: SYK) demonstrated its strength as a large-cap MedTech company at its Investor Day, leading Truist to boost its price target. Despite the positive outlook and strong Q3 2025 earnings, Truist maintained a neutral stance, preferring companies with faster earnings growth. Stryker continues to appeal to income investors with its 32-year dividend growth streak and commitment to margin expansion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |
| 2025-11-14 | BTIG | $410 | $410 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |
| 2025-11-14 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $35M sold (6 transactions in 90 days).
3. Long-term trend broken: trading 6.2% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.2B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 23.7 |
| Current P/E | 26.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.8% to -4.7% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-0.76), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.72% (CS: 8) | Weak |
| RSI_14 | 37.3 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.938x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $353.60
- **Stop Loss:** $339.06 (4.1% risk)
- **Target:** $368.14 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 34
- **Position Value:** $12,022.40
- **Portfolio %:** 12.02%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*